Smaller Pfizer? Yes, Please.

Having owned the operating unit for a decade, Pfizer (NYSE: PFE  ) is finally wondering what the heck to do with Capsugel, which develops formulations, like capsules for drugs, for it and other drugmakers.

The pharmaceutical giant is "reviewing strategic alternatives" for Capsugel, the unit it got when it acquired Warner-Lambert in 2000. That's company-speak for trying to figure out whether to sell the thing. If it's worth more to a generic-drug maker like Teva Pharmaceutical (Nasdaq: TEVA  ) or Mylan (Nasdaq: MYL  ) , or perhaps a private equity fund, then why not redeploy the capital elsewhere?

Pfizer is in the driver's seat here. Even if it decides to put Capsugel on the block, it still doesn't have to sell if the price isn't right. That's what Abbott Labs (NYSE: ABT  ) did when it shopped the vaccine business it got in the acquisition of Solvay. When no bidder with a high enough price tag arrived, it pulled the division off the table. Unless they're desperate for cash, companies are better off collecting revenue from unwanted units than giving them away for a song.

In the bigger picture, Pfizer might be better off selling much of its ancillary businesses, slimming down, and giving its drug discovery business a chance at growing. Diversification can work, but at some point a company becomes worth less than the sum of its parts. Selling off its animal health, consumer health, and nutrition businesses -- or spinning them off, like Bristol-Myers Squibb (NYSE: BMY  ) did with its baby formula business, Mead Johnson Nutrition (NYSE: MJN  ) -- might be a wise move.

After slimming down, Pfizer could have a decent shot at growing. It would have a smaller base to start from, making additions count more. But more importantly, the sales would generate considerable amounts of cash to spend. In order to grow, Pfizer needs to get drugs from outside its walls through acquisitions or licensing; both require cash.

Warren Buffett is willing to part with a little of his cash. Go figure.

Pfizer is a Motley Fool Inside Value recommendation. The Inside Value team scours high and low to bring you the best value stocks available. Check it out for free with a 30-day trial.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Teva and has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 08, 2010, at 12:32 PM, mgw6 wrote:

    I my book Pharmaplasia™ I discuss how rapid growth and organizational size in a complex business like pharmaceuticals and in a complex market like healthcare comes with management challenges that are often beyond the capabilities of most companies. Interesting that when companies get in trouble or are struggling, they start to downsize, not just for financial reasons but so they can better manage what they have. This often includes divesting of assets that make less strategic sense than merely adding bulk to the revenue line.

    www.PharmaReform.com

Add your comment.

DocumentId: 1325623, ~/Articles/ArticleHandler.aspx, 7/28/2014 6:42:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement